BioSpace News Archive

BARDA award for $642K helped Luminex accelerate development and validation

Organovo Holdings, Inc. convened, on March 26, 2020, the special meeting of stockholders and then adjourned the special meeting of stockholders until Tuesday, April 7, 2020 10:00 A.M. Pacific Time at www.virtualshareholdermeeting.com/ONVO2020 to solicit additional proxies for Organovo Proposal Nos. 1 and 4.

PDS Biotechnology Corporation (“PDS Biotechnology”) (Nasdaq: PDSB), a clinical-stage immuno-oncology company developing multiple therapies based on T-cell activating technology called Versamune® today announced its financial results for the full year ended December 31, 2019 and provided a business update.

ADVANZ PHARMA Corp. Limited (“ADVANZ PHARMA” or “the Company”), a global pharmaceutical company focused on serving the needs of patients and healthcare providers around the world with enhanced access to high quality, niche-established medicines, today announced that its limited voting shares were delisted from the Toronto

HEXO Corp (“HEXO” or the “Company”) (TSX: HEXO; NYSE: HEXO) plans to release its complete financial results for the quarter ended January 31, 2020 before market hours on Monday, March 30th, 2020 as well as host a webcast for investors beginning at 8:30 a.m. EST.

On 26 March 2020, the Board of Directors of Nordic Nanovector ASA approved the company’s financial statements for 2019.

Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, announced financial results for the year ended December 31, 2019.

Cognition Therapeutics, Inc. , a clinical-stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s disease (AD) and other neurodegenerative disorders, today announced that Kenneth I. Moch has stepped down as president and chief executive officer to assume an advisory role. Lisa Ricciardi has transitioned from her position on the Cognition Board of Directors to become acting chief executive officer. Mr

Mereo BioPharma Group plc today provided a general business update, including a current assessment of the impact of the coronavirus disease (COVID-19) pandemic on the business. The Company also announced a directorate change. Business Update The Company has provided an update on the setrusumab and alve

Battle-proven test used over 1 million times will accelerate clinical testing in United States - BGI’s test now has global approvals through US FDA, Europe’s CE-IVD, and China’s NMPA - Kits are currently being distributed to more than 70 countries and regions worldwide - Highly sensitive, rapid test with 3-hour turnaround time